PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) (NCT06665100)

🧪 Interventions in This Study

• PUL-042 (DRUG)
• Placebo (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Subjects will be eligible for entry into the study if a nasopharyngeal swab is positive for PIV, RSV, or hMPV (as a single pathogen or a mixed infection with rhinovirus) by molecular assay by a local laboratory AND subjects must fulfill the following inclusion criteria to be eligible for participation in the study:
2. Subjects with hematologic malignancies (i.e., leukemia, lymphoma, or multiple myeloma) or recipients of an allogeneic or autologous hematopoietic stem cell transplantation for one of the following diagnoses: leukemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, and myelodysplastic and myeloproliferative disorder.
3. Subjects who have undergone active cytotoxic chemotherapy within 6 months or subjects who are on an immunosuppressive therapy (e.g., alemtuzumab, ibrutinib, mycophenolate mofetil, corticosteroids ≥1mg/kg prednisone equivalent).
4. Subjects who are recipients of an allogeneic hematopoietic stem cell transplant (HSCT) must be deemed high risk with an Immunodeficiency Scoring Index (ISI) , of greater or equal to 4.
5. Subjects who are recipients of an autologous HSCT must be within 3 months of the transplant procedure.
6. Subjects must be symptomatic with upper or lower respiratory tract symptoms such as rhinorrhea, sore throat or cough and must be dosed within 6 days from the onset of symptoms.
7. Chest X-ray with a Radiologic Severity Index (RSI) score of 6 or lower.
8. Subjects must have pulse oximetry of hemoglobin saturation ≥ 93% on room air.
9. Spirometry (forced expiratory volume in one second \[FEV1\] and forced vital capacity \[FVC\]) ≥70% of predicted value.
10. Adult (≥ 18 years of age).
11. If female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception must be: practicing two effective methods of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. Abstinence is not classified as an effective method of birth control.
12. If female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. A pregnancy test must be negative at the Screening Visit, prior to dosing on Day 1.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (12 Sites)

• City of Hope National Medical Center — Duarte, California
• Northside Hospital — Atlanta, Georgia
• Johns Hopkins Hospital — Baltimore, Maryland
• Brigham and Women's Hospital — Boston, Massachusetts
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
• University of Minnesota — Minneapolis, Minnesota
• John Theurer Cancer Center — Hackensack, New Jersey
• Memorial Sloan Kettering Cancer Center — New York, New York
• Lineberger Cancer — Chapel Hill, North Carolina
• OU Health Physicians - Infectious Disease Clinic — Oklahoma City, Oklahoma
• University of Texas MD Anderson MD Anderson Cancer Center — Houston, Texas
• Fred Hutchinson Cancer Center — Seattle, Washington

📞 Contact the Study Coordinator

Phone: (484) 354-0615

Email: cbroom@pulmotect.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hematologic Malignancies

• A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant — Basking Ridge, New Jersey
• Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy — Duarte, California
• APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies — Jacksonville, Florida
• IVIG for Infection Prevention After CAR-T-Cell Therapy — Duarte, California
• Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies — Madison, Wisconsin

Explore by condition: All Hematologic Malignancies clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.